PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Subdivisions of Program Areas, these track general higher level sub-classifications of expenditure.
Subdivisions of Major categories, these are the most detailed expenditure data.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010
Joint Clinical Research Centre (JCRC) pioneered the use of antiretroviral therapy in Sub Saharan Africa as early as 1992 when it conducted the first ARV therapy trial in Africa aimed at determining the safe and effective use of Zidovudine, a new drug by then. By 2003, JCRC was the biggest provider of ART in Uganda with close to 10,000 patients enrolled on ART. JCRC has managed to reach a number of remote and hard to reach areas with high HIV prevalence. ART sites have been established in IDP camps in Gulu and Pader districts; the marginalized communities of Batwa in Bwindi, the fishing community in Sesse islands and hard to reach areas like Kaabong and Moyo district hospitals.The Program for Timetable for Regional Expansion of Anti-retroviral therapy (TREAT) is a Seven Year Program implemented through a co-operative agreement between USAID/Uganda and the JCRC, which ends on September 30, 2010. The TREAT program works closely with the MOH and HIV/AIDS partners to increase access and build capacity for ART in 46 satellite clinics and 25 outreaches. 5 TREAT sites have been transitioned to the new district based HIV/TB programs in STAR -East, and STAR- East Central (Kapchorwa, Kamuli and Iganga district hospital). Apac and Patongo HCIII in Pader were transitioned to NUMAT Project. JCRC established Six Regional Centres of Excellence (RCEs) to ensure, to ensure access to quality ART and comprehensive laboratory services. RCEs include; Kakira, Mbale, Gulu, Fort Portal, Mbarara and Kabale, and a mini RCE in Mubende.
The TREAT program has successfully expanded access to ART, increasing the number of people supported on ART from under 10,000 in 2003 to over 32,189 currently accessing ART. With support from Clinton Foundation Initiative,JCRC will enroll new OVCs on ART. JCRC will not enroll new adults on ART but will refer them to other partners and MOH facilities that have capacity to enroll new clients.